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Abstract
Purpose To determine the maximum-tolerated dose
(MTD) of a 24-h continuous infusion of 5-Xuorouracil
(5-FU) when administered in combination with a Wxed
weekly dose of docetaxel and cisplatin in patients with
advanced gastric cancer.
Methods Patients with advanced gastric adenocarcinoma
(n = 21) received a weekly regimen of docetaxel, cisplatin
and 5-FU (DCF) for 3 consecutive weeks every 4 weeks.
The doses of docetaxel and cisplatin were Wxed at 33.3 and
30 mg/m2, respectively. The dose of 5-FU was increased
from a starting dose of 1,000 mg/m2 to the MTD.
Results A total of 53 cycles of chemotherapy were admin-
istered (median = 3 cycles/patient). The MTD of 5-FU was
1,750 mg/m2. All 21 patients were assessed for toxicity
and 19 patients (90%) were evaluated for response. Both
grade 3–4 hematologic and non-hematologic toxicities
occurred in less than 10% of patients and there were no
treatment-related deaths. Among the 19 patients, we
observed 1 complete and 4 partial responses for an overall
response rate of 26% (95% CI: 6–46%). This rate increased
to 39% (95% CI: 12–66%) in 13 chemotherapy-naïve
patients.
Conclusions A consecutive weekly DCF regimen at
4-week intervals appears feasible for advanced gastric cancer
with a favorable toxicity proWle. The recommended doses
are 33.3 mg/m2 of docetaxel, 30 mg/m2 of cisplatin and
1,500 mg/m2 of a 24-h continuous intravenous infusion of
5-FU. The response of this weekly regimen in our study
was favorable and deserved further investigation in a phase
II trial.
Keywords Gastric cancer · Phase I · 5-Fluorouracil · 
Docetaxel · Cisplatin
Introduction
Advanced gastric cancer remains an incurable disease with
a median survival rate of 6–9 months [1]. Combination che-
motherapy is largely acknowledged as an eVective treat-
ment for patients with unresectable or metastatic gastric
cancer. The randomized studies showed that, compared to
the best supportive care, chemotherapy improves survival
and quality of life for the patients with good performance
status [1–3]. Although a large number of combination regi-
mens have been evaluated in clinical trials, it is still hard to
determine which is best as a standard treatment protocol.
Recently, docetaxel showed strong anti-cancer activity
against gastric cancer in both Wrst- and second-line treat-
ment settings [4–6]. In a multi-center, open-label, random-
ized, phase III study (V325), compared to the control arm
of the CF regimen, a combination of docetaxel, cisplatin
and 5-Xuorouracil (5-FU) showed higher eYcacy in terms
of response rate, time to progression and overall survival
[7]. According to this clinical trial, combination of doce-
taxel, cisplatin and 5-FU (DCF) is an eVective treatment
approach in patients with advanced gastric cancer. But,
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neutropenia (82 versus 57%) and febrile neutropenia infec-
tion (29 versus 12%). Other toxicities of DCF treatment
regimen include eVects on the gastrointestinal system, espe-
cially mucositis and diarrhea. In the V325 study, these two
grade 3–4 toxic reactions developed in about 20% of
patients in the DCF arm. Both mucositis and diarrhea are
dose-limiting toxicities (DLT) of 5-FU (when given by
continuous infusion) and are worsened by the addition of
docetaxel.
One way of reducing the myelosuppressive toxicity of
docetaxel is to administer it weekly. In studies of non-
small-cell lung cancer patients, weekly use of docetaxel
signiWcantly reduced hematologic toxicity without compro-
mising eYcacy [8, 9]. Several studies on colorectal cancer
reported low incidences of toxicities for weekly 5-FU
administration [10, 11]. Based on those results, a weekly
DCF (wDCF) regimen is considered optimal for treating
metastatic gastric cancer, but a full-scale clinical assess-
ment is needed. Due to the poor tolerability of the patients
with gastric cancer to chemotherapy [7], we conducted a
phase I dose-escalating study involving a 24-h continuous
infusion of 5-FU in combination with a Wxed dose of
weekly docetaxel and cisplatin in patients with advanced
gastric cancer. The purpose of this study was to determine
the maximum-tolerated dose (MTD) of 5-FU and to evalu-
ate the toxicity of the above-described weekly regimen.
Patients and methods
Patients
Patients with histologically conWrmed, unresectable, recur-
rent and/or metastatic gastric adenocarcinoma were eligible
for inclusion in this study. Additional inclusion criteria
included: age 18–70; ECOG performance status ·2;
adequate bone marrow function (absolute neutrophil count
and platelet count ¸1.5 £ 109 and 75 £ 109 L1, respec-
tively); hepatic function (total serum bilirubin ·1.5 mg/dL,
transaminases ·1.5 times upper normal limit) and adequate
renal function (calculated creatinine clearance ¸60 mL/min).
Measurable disease was not mandatory for inclusion in
the study. Patients who had previously received chemo-
therapy were also eligible, except those with prior regimens
that contained taxanes, or those who had received a 24-h
continuous infusion of 5-FU. Patients were required to
have fully recovered from the toxicity of previous chemo-
therapy treatments except alopecia. The study protocol
was approved by the ethics and scientiWc committees of
Cancer Hospital Fudan University and signed informed
consent forms were obtained from all patients prior to their
enrollment.
Study designs
The treatment regimen consisted of weekly administration
of docetaxel and cisplatin, and 24-h continuous infusion of
5-FU on days 1, 8 and 15. This treatment was repeated
every 4 weeks and continued until the disease progressed or
until unacceptable toxicity developed. Docetaxel was
administered at a dose of 33.3 mg/m2 as an 1-h infusion.
Dexamethasone (8 mg p.o. 12 h before docetaxel treatment,
30 min before the docetaxel treatment, and 12 h after doce-
taxel injection) was given to avoid hypersensitivity reactions
and to prevent docetaxel-induced Xuid retention. Cisplatin
was infused at a dose of 30 mg/m2 for 30 min after appro-
priate hydration. The starting dose of 5-FU was 1,000 mg/m2
as a 24-h continuous infusion. In the absence of DLT, dose
escalation in additional cohorts continued at a dose increase
of 250 mg/(m2 dose). All patients received  5-HT3 inhibi-
tors prior to chemotherapy. A peripherally inserted central
catheter (PICC) was recommended for intravenous access.
Only the Wrst cycle of treatment was evaluated to deter-
mine DLT. DLTs were deWned as follows: grade 4 neutro-
penia and/or thrombocytopenia, any episodes of febrile
neutropenia, any grade 3 or 4 non-hematologic toxicities,
excluding nausea/vomiting and alopecia. Patients were
enrolled in cohorts of three to receive the combination che-
motherapy. If one DLT occurred, three additional patients
had to be treated at the same dose level. If two or more
DLTs occurred at a given dose level, then that level was
recorded as the MTD. The dose just below the MTD
became the recommended dose for further evaluation. A
minimum of six patients was required for establishing the
MTD. For patients who had reached a DLT, treatment was
resumed at the next lower dose after resolving symptoms of
previous toxic reactions.
Patient evaluation
Baseline evaluations included complete medical history,
physical examination, chest radiographs, complete blood
cell count with diVerential and platelet counts, complete
blood chemistry and an ECG. Computed tomography (CT)
scans of the abdomen and pelvis were done at study entry.
Additional imaging studies were done whenever clinically
indicated. During treatment, complete blood cell counts
were routinely done twice a week and performed daily in
case of grade 3–4 neutropenia, thrombocytopenia or febrile
neutropenia, until hematologic recovery. Blood chemistry
analyses and physical examinations were done when clini-
cally indicated. Toxicities were recorded according to the
NCI common toxicity criteria (NCI-CTC Version 3.0).
When applicable, imaging studies were done after every
two cycles of treatment to evaluate tumor response.
Responses were documented according to the RECIST123
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starting from the date of starting treatment and ending
either on the date when disease progression was docu-
mented, or on the date of death or of last contact. Overall
survival (OS) was deWned as starting from the treatment
start date and ending on the date of death. The Kaplan–
Meier method was used for all survival analyses.
Results
Patient characteristics
Twenty-one patients (12 males and 9 females) with meta-
static gastric cancer were enrolled. Patient characteristics
are shown in Table 1. All patients were assessable for tox-
icity and the vast majority (90%) had an ECOG perfor-
mance status of 0 to 1. Thirteen (62%) patients were initially
diagnosed with metastatic disease and seven of eight
patients received adjuvant chemotherapy after a curative
gastrectomy. Prior to enrollment, palliative chemotherapy
had been given to eight (38%) patients and each regimen
included one type of Xuoropyrimidine. The most common
manifestations of disease were tumor at the primary site,
lymph node involvement and peritoneal and liver metas-
tases. Nineteen (90%) patients had measurable disease
according to the RECIST criteria, whereas two other
patients only presented with malignant ascites and pleural
eVusion.
Toxicity
In total, 53 cycles of chemotherapy were given, with a
median of three cycles per patient (range 1–6). Table 2 pre-
sents patient accrual and tolerance per dose level. Of three
patients enrolled on dose level 1 (5-FU 1,000 mg/m2), none
experienced DLTs. At dose level 2 (5-FU 1,250 mg/m2)
and dose level 3 (5-FU 1,500 mg/m2), one DLT (grade 3
diarrhea and grade 4 neutropenia) was observed at each
dose level (involving 12 patients). Dose escalation thus
continued to dose level 4 (5-FU 1,750 mg/m2). At this
level, a heavily treated patient had grade 3 mucositis. Of
the three additional patients enrolled, a 43-year-old male
developed moderate angina pectoris and palpitations on the
third week of treatment. ECG changes suggested inferior
myocardial ischemia and echocardiograms and cardiac
enzymes were normal. The symptoms resolved spontane-
ously without medical intervention. Subsequently, the
patient received a docetaxel and cisplatin combination regi-
men and no cardiac events occurred. Since this young
patient had no prior history of cardiac disease, the cardiac
ischemia was probably due to having reached a DLT of
5-FU. As a result of the two DLTs that occurred at dose
level 4, the MTD was considered to have been reached and
dose escalation was stopped. Therefore, the recommended
dose for further phase II studies of this chemotherapeutic
combination was deWned as 33.3 mg/m2 of weekly
docetaxel, 30 mg/m2 of cisplatin and 1,500 mg/m2 of 24-h
continuous 5-FU infusion.
Table 3 shows the incidence rate of major toxic reactions
in all treatment cycles. There was no treatment-related mor-
tality. Hematologic toxicity was mild. Grade 3–4 neutrope-
nia and anemia occurred in two patients. No patient
experienced febrile neutropenia or neutropenic infection.
Non-hematologic toxicity was manageable and grade 3–4
toxicity was uncommon. Two patients with grade 3 muco-
Table 1 Patient characteristics
Characteristics n (%)












Curative gastrectomy 8 (38)
Palliative gastrectomy 2 (10)
Prior adjuvant chemotherapy 7 (33)
Prior adjuvant radiotherapy 0
Prior palliative chemotherapy 8 (38)
Disease extent
Locally advanced 0
Metastatic disease 21 (100)













Measurable disease 19 (90)123
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management. The docetaxel-related toxic reactions of
hyperlacrimation and Xuid retention were not observed in
all patients. As previously mentioned, one patient devel-
oped cardiac ischemia.
Response
Tumor responses are summarized in Table 4. Among the 19
patients with measurable disease, there was one complete
response (CR) and there were four partial responses (PR),
with an overall response rate of 26% (95% CI: 6–46%).
These Wve patients were all chemo-naïve. When six previ-
ously treated patients were excluded, the overall response
rate increased to 39% (95% CI: 12–66%). Moreover, Wve
(26%) patients had stable disease (SD) and four had pro-
gressive disease (PD).
Five patients (26%) did not undergo a response assess-
ment and three of them developed DLT and dropped out of
the protocol treatment process, either due to the patients’
refusal to continue or the physician’s discretion. Another
two patients did not receive further chemotherapy after one
cycle; one stopped treatment because of deteriorated
performance status and for unknown reasons, the other
patient never returned to complete his or her role in the
experiment. At the time of this analysis, the median time to
progression (TTP) and median overall survival (OS) had
not yet been determined.
Discussion
The results of the present phase I study clearly demonstrate
that a DCF regimen can be safely and relatively comfort-
ably administered on a weekly basis for 3 consecutive weeks
at 4-week intervals. Combined with a Wxed dose of doce-
taxel [33.3 mg/(m2 week)] and cisplatin [30 mg/(m2 week)],
the recommended dose of 5-FU for further phase II studies
is 1,500 mg/(m2 week). The dose intensity of 5-FU at this
level is comparable to that of the standard  5-FU schedule
[750 mg/(m2 day), days 1–5] used in the V325 study [7].
Our study used a Wxed dose of weekly docetaxel
[33.3 mg/(m2 week)]. This dose was chosen according to a
randomized phase III study which showed that, compared
with administering Docetaxel three times per week, a
weekly dose of docetaxel, as a second-line treatment for
advanced NSCLC, is associated with signiWcantly less





No. of patients DLTs
Total With DLT Event Grade
1 1,000 3 0 Diarrhea 3
2 1,250 6 1 Neutropenia 4
3 1,500 6 1 Mucositis 3
4 1,750 6 2 Cardiac ischemia 3
Table 3 Toxicity (worst grade per patient in all cycles)
Grade
Dose level 1 (n = 3) Dose level 2 (n = 6) Dose level 3 (n = 6) Dose level 4 (n = 6)
0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4
Neutropenia 1 0 2 0 0 3 1 1 1 0 4 0 1 0 1 2 2 2 0 0
Anemi 0 2 0 1 0 2 3 1 0 0 5 0 1 0 0 1 4 0 1 0
Thrombocytopenia 2 1 0 0 0 6 0 0 0 0 5 0 1 0 0 5 1 0 0 0
Mucositis 3 0 0 0 0 6 0 0 0 0 5 0 1 0 0 5 0 0 1 0
Diarrhea 1 1 1 0 0 5 0 0 1 0 2 3 1 0 0 6 0 0 0 0
Nausea 1 1 1 0 0 3 3 0 0 0 2 1 1 1 1 5 0 1 0 0
Vomiting 1 1 1 0 0 5 1 0 0 0 3 0 0 2 1 5 0 1 0 0
Fatigue 3 0 0 0 0 3 2 1 0 0 3 2 1 0 0 5 0 0 1 0
Fluid retention 3 0 0 0 0 6 0 0 0 0 6 0 0 0 0 6 0 0 0 0
Hyperlacrimation 3 0 0 0 0 6 0 0 0 0 6 0 0 0 0 6 0 0 0 0
Cardiac ischemia 3 0 0 0 0 6 0 0 0 0 6 0 0 0 0 5 0 0 1 0
Table 4 Tumor response
Response No. of patients (%)
All patients (n = 19) Chemo-naïve (n = 13)
CR 1 (5) 1 (8)
PR 4 (21) 4 (31)
SD 5 (26) 3 (23)
PD 4 (21) 2 (15)
Not available 5 (26) 3 (23)123
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eYcacy or quality of life [8]. Two other phase I studies of
patients with advanced gastric cancer found that the MTD
of docetaxel was 40 mg/m2 per week [10, 13]. However,
both studies showed a much higher incidence of grade 3–4
neutropenia than our study. Furthermore, in the later study,
febrile neutropenia occurred in 4 of 19 patients and 1
patient died from septic shock [13]. The dose intensity of
docetaxel that was used in our protocol was equivalent to
75 mg/m2 every 3 weeks, which is typically used in a stan-
dard DCF regimen. Only 2 of 21 patients in our study
developed grade 3–4 neutropenia and there was no apparent
febrile neutropenia.
Another goal of our experimental medication protocol
was to alleviate gastrointestinal toxicity by changing the
5-FU administration schedule. In V325 study, 5-FU is
administered at the dose of 750 mg/(m2 day) as a continu-
ous intravenous infusion on day 1 through 5 and grade 3–4
mucositis or diarrhea was reported in about one-Wfth of the
patients. Based on the experience of treating colorectal can-
cer with chemotherapy, alteration of the 5-FU infusion
level may lead to a diVerent toxicity proWle. At least two
studies reported mild hematologic and non-hematologic
toxicities when 5-FU was used as a 24-h infusion combined
with leucovorin (AIO regimen), which may increase both
the eYcacy of 5-FU and its toxicity [10, 11]. In both stud-
ies, less than 10% of patients with colorectal cancer had
grade 3–4 mucositis and diarrhea, when they received
weekly 5-FU administration. Our results show that, among
all 21 patients, only 2 of them developed grade 3 mucositis
or diarrhea, which are dose-limiting toxicities from the
continuous infusion of 5-FU. Obviously, a modiWed weekly
5-FU schedule may have contributed to such a low propor-
tion of these two toxicities in our study. Another phase I
study with a similar design also concurred with our Wndings
[14]. That study used a weekly DFLP chemotherapy
regimen (docetaxel, 5-FU/leucovorin and cisplatin) for 2
consecutive weeks every 3 weeks in patients with advanced
gastric cancer. None of the patients in this study developed
mucositis or diarrhea of grade 3–4. But the study also
showed a high incidence of grade 3–4 neutropenia, occur-
ring in 45% of the patients, which was much higher than
our study.
Since 19 (90%) patients had measurable disease levels, a
response evaluation could be performed in this patient pop-
ulation. The 26% overall response rate achieved by our
weekly DCF regimen is somewhat lower than the response
rate (37%) in the V325 study, possibly because patient
characteristics in these studies were a bit diVerent [7]. The
V325 study only enrolled chemo-naïve patients, while
nearly one-third of the patients in the present study had
already been receiving prior chemotherapy at the onset of
the study. When six previously treated patients were
excluded from the analysis, the response rate became 39%,
which is in line with the rate in the V325 study. However,
due to the small sample size of this phase I trial, we need to
conWrm the eYcacy of this particular weekly DCF regimen
in a subsequent phase II study.
In conclusion, the results of this trial indicate that treat-
ment with three consecutive weekly DCF treatments,
repeated every 28 days, is a feasible chemotherapy regi-
men with a favorable toxicity proWle. The recommended
doses are 33.3 mg/m2 of docetaxel, 30 mg/m2 of cisplatin
and 1,500 mg/m2 of a 24-h continuous infusion of 5-FU.
The response of this weekly regimen in our study was
favorable and deserved further investigation in a phase II
trial.
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